Bristol-Myers Squibb (BMY) Reports CheckMate-214 Study Evaluating Opdivo in Combination with Yervoy Meets Co-Primary Endpoint, Demonstrating Superior Overall Survival Compared to Sunitinib
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced today that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
